Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 32Leukemia 21Lymphoma 15Prostatic Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 10Lymphoma, Large B-Cell, Diffuse 9Leukemia, Monocytic, Acute 8Recurrence 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia, Erythroblastic, Acute 7Congenital Abnormalities 7Myelodysplastic Syndromes 6Leukemia, Megakaryoblastic, Acute 6Lymphoma, Large-Cell, Immunoblastic 5Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Blast Crisis 4Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2HIV Infections 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Cyclosporine 2Cyclophosphamide 2venetoclax 1ruxolitinib 1letermovir 1ibrutinib 1fludarabine 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Sirolimus 1Mitoxantrone 1Melphalan 1Lisaftoclax 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Carmustine 1Biopsy 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Prolymphocytic, T-Cell × Mitoxantrone × Clear all
NCT01186640 2022-01-05

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

German CLL Study Group

Phase 2 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡